Wei, James Cheng-Chung
China Medical University · Chung Shan Medical University Hospital · Chung Shan Medical University
2 papers on CoChatORCID 0000-0002-1235-0679
Most cited papers
- Verified
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Baeten, D., Østergaard, M., Wei, J. C.-C., Sieper, J., Järvinen, P., Tam, L.-S., Salvarani, C., Kim, T.-H., Solinger, A., Datsenko, Y., et al. (2018) · Annals of the Rheumatic Diseases
Spondyloarthritis Studies and TreatmentsPsoriasis: Treatment and Pathogenesis
Cited by 390
- Verified
Glucagon-like peptide-1 receptor agonists and risk of sight-threatening retinopathy in Taiwanese population: a propensity based cohort study
Yen, F.-S., Wei, J. C.-C., Shih, Y.-H., Hung, Y.-T., Hsu, T.-J., Hsu, C.-C., & Hwu, C.-M. (2024) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Diabetes Treatment and ManagementRetinal Diseases and Treatments
Cited by 13
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free